



Insulin ELISA

For the quantitative determination of insulin in serum and plasma.

For In Vitro Diagnostic use within the United States of America.

This product is for Research Use Only outside of the United States of America.

Catalog Number: 80-INSHU-E01.1, E10.1

Size: 96 wells, 10 x 96 wells

Version: May 29, 2018

INTENDED USE

The ALPCO Insulin ELISA is designed for the quantitative determination of insulin in serum and plasma.

PRINCIPLE OF THE ASSAY

The ALPCO Insulin ELISA is a sandwich type immunoassay. The 96-well microplate is coated with a monoclonal antibody specific for insulin. The standards, controls, and samples are added to the microplate wells with the Detection Antibody. The microplate is then incubated on a microplate shaker at 700-900 rpm. After the first incubation is complete, the wells are washed with Wash Buffer and blotted dry. TMB Substrate is added, and the microplate is incubated a second time on a microplate shaker at 700-900 rpm. Once the second incubation is complete, Stop Solution is added, and the optical density (OD) is measured by a spectrophotometer at 450 nm. The intensity of the color generated is directly proportional to the amount of insulin in the sample.

MATERIALS SUPPLIED

80-INSHU-E01.1		
Component	Quantity	Preparation
Microplate (96 wells)	12 x 8 strips	Ready to use
Zero Standard (0 µIU/ml)	5 ml	Ready to use
Standards (A-E) (3, 10, 30, 100, 200 µIU/ml)	5 x 1 ml	Ready to use
Diabetes Control Levels 1 and 2*	1 vial each	Lyophilized*
Detection Antibody	11 ml	Ready to use
Wash Buffer Concentrate	40 ml	21X
TMB Substrate	12 ml	Ready to use
Stop Solution	12 ml	Ready to use
Plate Sealers	3	Ready to use

*Please refer to the Certificate of Analysis enclosed with each kit for lot-specific control ranges and reconstitution volumes.

80-INSHU-E10.1		
Component	Quantity	Preparation
Microplates (96 wells)	10 x (12 x 8 strips)	Ready to use
Zero Standard (0 μ IU/ml)	5 mL	Ready to use
Standards (A-E) (3, 10, 30, 100, 200 μ IU/ml)	5 x 1 mL	Ready to use
Diabetes Control Levels 1 and 2*	1 vial each	Lyophilized*
Detection Antibody	105 mL	Ready to use
Wash Buffer Concentrate	2 x 200 mL	21X
TMB Substrate	120 mL	Ready to use
Stop Solution	120 mL	Ready to use
Plate Sealers	20	Ready to use

*Please refer to the Certificate of Analysis enclosed with each kit for lot-specific control ranges and reconstitution volumes.

MATERIALS REQUIRED

- Precision pipettes for dispensing 25 -100 μ L (with disposable tips)
- Repeating or multi-channel pipette for dispensing 100 μ L
- Volumetric containers and pipettes for reagent preparation
- Distilled or deionized water for reagent preparation
- Microplate washer or wash bottle
- Microplate shaker capable of 700-900 rpm
- Microplate reader with 450 nm filter
- Vortex for sample preparation

PRECAUTIONS

1. The human blood products incorporated into this kit have been tested for the presence of HIV (human Immunodeficiency virus), HBV (Hepatitis B virus), and HCV (Hepatitis C virus). Test methods for these viruses do not guarantee the absence of a virus; therefore, all reagents should be treated as potentially infectious. Handling and disposal should be in accordance with all appropriate national and local regulations for the handling of potentially biohazardous materials.
2. All materials derived from animal sources are BSE negative. However, all materials should be treated as potentially infectious.
3. Avoid direct contact with skin.
4. This product is not for internal use.
5. Avoid eating, drinking, or smoking when using this product.
6. Do not pipette any reagents by mouth.
7. Reagents from this kit are lot-specific and must not be substituted.
8. Do not use reagents beyond the expiration date.
9. Variations to the test procedure are not recommended and may influence the test results.

STORAGE CONDITIONS

The kit should be stored at 2-8°C. The kit is stable until the expiration date on the box label.

SAMPLE HANDLING

Serum and plasma (heparin or EDTA) samples are appropriate for use in this assay. No dilution or treatment of the sample is required. However, if a sample has a greater concentration of insulin than the highest standard, the sample should be diluted in Zero Standard and the analysis should be repeated.

Samples can be stored at 2-8°C for 24 hours prior to analysis. Storage at < -20°C for longer periods is recommended. Avoid repeated freeze/thaw cycles.

It is recommended to 1) thoroughly vortex each sample before use and 2) perform pipetting actions without pausing.

REAGENT PREPARATION

All reagents must be equilibrated to room temperature prior to preparation and subsequent use in the assay.

Wash Buffer Concentrate is to be diluted with 20 parts distilled water. For example, to prepare Working Strength Wash Buffer, dilute 20 ml of Wash Buffer Concentrate (21X) with 400 mL of deionized water. Working Strength Wash Buffer is stable for 4 weeks at room temperature (18-25°C).

Diabetes Controls (Levels 1 and 2) are provided in a lyophilized form. Please refer to the Certificate of Analysis provided with each kit for the appropriate volume of deionized water for reconstitution. Close the vial with the rubber stopper and cap, gently swirl the vial, and allow it to stand for 30 minutes prior to use. The contents of the vial should be in solution with no visible particulates. The reconstituted controls are stable for 7 days stored at 2-8°C. If desired, the controls can be stored at ≤ -20°C in aliquots for up to 6 months. The controls should not be repeatedly frozen and thawed.

QUALITY CONTROL

It is recommended that the Controls provided with the ALPCO Insulin ELISA be included in every assay. The concentration ranges of the controls are provided on the Certificate of Analysis provided with each kit; however, it is recommended that each laboratory establishes its own acceptable ranges.

ASSAY PROCEDURE

All reagents and microplate strips should be equilibrated to room temperature (18-25°C) prior to use. Gently mix all reagents before use. A standard curve must be performed with each assay run and with each microplate if more than one is used at a time. All standards, controls, and samples should be run in duplicate.

1. The microplate should be equilibrated to room temperature prior to opening the foil pouch. Designate enough microplate strips for duplicate determinations of the standards, controls, and samples. The remaining microplate strips should be stored at 2-8°C in the tightly sealed foil pouch containing the desiccant.
2. **Pipette 25 µL** of each standard, control, and sample into their respective wells. See *Reagent Preparation* for control reconstitution instructions.
3. **Pipette 100 µL** of Detection Antibody into each well.
4. Cover microplate with a plate sealer and **incubate for 1 hour** at room temperature, shaking at 700-900 rpm on a microplate shaker.
5. Decant the contents of the wells and **wash the microplate 6 times** with 350 µl of Working Strength Wash Buffer per well (see *Reagent Preparation*) using a microplate washer. Alternatively, fill the wells with Working Strength Wash Buffer using a wash bottle (do not use a multichannel pipette). Between washes, invert the microplate to discard the liquid and firmly tap the inverted microplate on absorbent paper towels. After the final wash, (automated or manual), remove any residual Wash Buffer and bubbles from the wells by inverting and firmly tapping the microplate on absorbent paper towels.
6. **Pipette 100 µL** of TMB Substrate into each well.
7. Cover microplate with a plate sealer and **incubate for 15 minutes** at room temperature, shaking at 700-900 rpm on a microplate shaker.
8. **Pipette 100 µL** of Stop Solution into each well and gently shake the microplate to mix the contents. Remove any bubbles before proceeding with the next step.
9. Place the microplate in a microplate reader capable of reading the absorbance at 450 nm. The microplate should be analyzed immediately after the addition of the Stop Solution, and no longer than 30 minutes after.

CALCULATION OF RESULTS

Construct a standard curve from the standards. The Zero Standard should be used as a blank with its average value subtracted from each well. It is recommended to use a software program to calculate the standard curve and to determine the concentration of the samples.

The Insulin ELISA is a ligand binding assay, with responses exhibiting a sigmoidal relationship to the analyte concentration. Currently accepted reference models for such curves use a 4 or 5-parameter logistic (pl) fit, as these models optimize the accuracy and precision across a greater range. Although cubic spline and other models are acceptable methods, they generally show less intra-assay accuracy and precision at the low and high ends of the range.


In the example below, a 5-pl curve fit was used to maximize the accuracy and precision of samples with low concentrations. However, the accuracy and precision of all models are limited at the lowest and highest ends of the detectable range due to the influence of individual laboratory conditions. As a result, caution should always be used when interpreting results where the analyte response becomes non-linear.¹

TYPICAL STANDARD CURVE

The following results are provided for demonstration purposes only and cannot be used instead of data obtained with the assay. A standard curve must be performed with each assay run and plate tested.

Standard	Conc. (µIU/mL)	OD
Zero	0	0
A	3	0.043
B	10	0.134
C	30	0.412
D	100	1.321
E	200	2.644

Blank OD	0.051
----------	-------



EXPECTED VALUES

The ALPCO Insulin ELISA is calibrated to the WHO insulin 1st IRP 66/304. Prior studies have determined normal insulin ranges to be 5 – 25 µIU/mL. It is recommended that each laboratory establish its own normal range for its individual patient population.

Conversion for Human Insulin from International Units (IU) to micrograms:

1 IU of Human Insulin = 6 nmol = 34.8 µg Insulin

PERFORMANCE CHARACTERISTICS

Sensitivity

The analytical sensitivity was determined by calculating the mean + 2 standard deviations for 22 replicates of the Zero Standard. The sensitivity of the assay is 0.399 µIU/mL.

Precision: Within run (intra-assay) variation

The within run precision is expressed as the percentage coefficient of variation (CV %). This was determined based on the mean and standard deviation of 22 replicates of a sample run in a single assay. The table below shows the results of 3 samples that span the range of the assay.

	Sample 1	Sample 2	Sample 3
Mean	4.86 µIU/mL	77.89 µIU/mL	115.63 µIU/mL
Std. Dev.	0.50 µIU/mL	2.46 µIU/mL	5.93 µIU/mL
CV %	10.3	3.2	5.1
n	22	22	22

Precision: Between run (inter-assay) variation

The between run precision is expressed as the percentage coefficient of variation (CV %). This was determined based on the mean and standard deviation across 10 assays of duplicate measurements of a single sample. The table below shows the results of 3 samples that span the range of the assay.

	Sample 1	Sample 2	Sample 3
Mean	5.10 µIU/mL	72.83 µIU/mL	116.98 µIU/mL
Std. Dev.	0.85 µIU/mL	6.18 µIU/mL	7.83 µIU/mL
CV %	16.6	8.5	6.7
n	20	20	20

Linearity

The linearity of the assay was determined by preparing dilutions of a sample with high insulin concentrations with the Zero Standard. The expected values were compared to the obtained values to determine a percent recovery. The average recovery was 105 - 108%.

Spike and Recovery

The spike and recovery of the assay was determined by adding various known amounts of insulin to a sample. This spiked sample was evaluated in the assay and the measured concentration was compared to the expected concentration (endogenous + spiked). The range of recovery was 89 – 99%.

Specificity

The table below indicates the analyte and the percent cross-reactivity observed in the assay.

Analyte	% Cross-reactivity*
Human insulin	100
Human C-peptide	ND
Human proinsulin (intact)	ND
Humalog	0.35
Novolog	54.5
Humulin R	72.5
Humulin N	241
Lantus	42.5
Porcine insulin	175
Porcine C-peptide	ND
Human IGF-1	< 0.05
Human IGF-2	< 0.04
Mouse Insulin	ND

Rat Insulin	ND
-------------	----

*ND = not detected.

Hook Effect

No high does hook effect was observed with analyte concentrations up to 36,597 $\mu\text{IU/mL}$.

Limitations


The effect of various potentially interfering substances was determined in the ALPCO Insulin ELISA. The table below indicates the highest concentration tested with no interference in the assay.

Interfering Substance	Concentration Tested
Hemoglobin	500 mg/dL
Bilirubin	15 mg/dL
Triglycerides	500 mg/dL
Gamma globulins (human)	6 mg/dL
Heparin	6,000 Units/dL

REFERENCES

1. Finlay JWA, Dillard RF. Appropriate Calibration Curve Fitting in Ligand Binding Assays. *AAPS Journal*. 2007; 9(2): E260-E267.

SHORT ASSAY PROTOCOL



Total Time = 1 hour, 15 minutes